Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy in the world, representing approximately 20% of all skin cancers. Immunosuppression is a well-established risk factor, contributing not only to the development of new cSCC lesions but also to more aggressive disease and increased mortality. Despite the National Comprehensive Cancer Network (NCCN) and the American Joint Committee on Cancer (AJCC) 8th edition updates recognizing immunosuppression as a risk factor for cSCC, standardized management protocols for these high-risk patients remain limited. As a result, treatment of this already high-risk group remains a significant challenge and highlights the need for dedicated research and attention to improve outcomes in this patient population. This review explores the current knowledge regarding cSCC in IS patients, outlines key gaps in the knowledge, and highlights recent clinical trials to further guide the evaluation and management of these patients.
皮肤鳞状细胞癌是全球第二常见的皮肤恶性肿瘤，约占所有皮肤癌的20%。免疫抑制是其明确的危险因素，不仅促进新发皮肤鳞状细胞癌病变的形成，还会导致疾病更具侵袭性并增加死亡率。尽管美国国家综合癌症网络和第八版美国癌症联合委员会分期系统已将免疫抑制列为皮肤鳞状细胞癌的危险因素，但针对这类高危患者的标准化管理方案仍然有限。因此，对这一高危群体的治疗仍面临重大挑战，凸显出开展专项研究和关注以改善此类患者预后的必要性。本综述探讨了当前关于免疫抑制患者皮肤鳞状细胞癌的认知，指出了该领域的关键知识空白，并重点介绍了近期临床试验进展，以期为这类患者的评估与管理提供进一步指导。
Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients
肿瘤(癌症)患者之家